Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention.
The renin-angiotensin-aldosterone system (RAAS) plays a significant role in pathophysiology of multiple disease states. RAAS blockade is beneficial in patients with hypertension, acute myocardial infarction, chronic heart failure, stroke, and diabetic renal disease. RAAS blockade with the combination angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) has demonstrated conflicting results in recent clinical trials. This article reviews the latest evidence of isolated ACEI or ARB use, their combination, and the role of aldosterone blockers and direct renin inhibitors in patients at risk, and makes recommendations for their use in the prevention of morbidity and mortality in cardiovascular disease.
Cardiovascular Research and Education, Scottsdale Healthcare, Scottsdale, AZ, USA. kvijaymd@gmail.com
Krishnaswami
K
Vijayaraghavan
Prakash
P
Deedwania
D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D006801:Humans; D012084:Renin-Angiotensin System / Q000187:drug effects*; D016896:Treatment Outcome
D057911:Angiotensin Receptor Antagonists